metformin + phentermine + topiramate

This is a combination of three drugs—metformin, phentermine, and topiramate—used together for weight management or metabolic indications. Metformin is a biguanide antihyperglycemic agent that decreases hepatic glucose production and improves insulin sensitivity. Phentermine is a sympathomimetic amine anorectic that suppresses appetite via central nervous system stimulation. Topiramate is an anticonvulsant with weight loss properties, thought to act through modulation of voltage-gated ion channels and enhancement of GABA activity in the brain. While the fixed-dose combination of phentermine plus topiramate (marketed as Qsymia) is approved for chronic weight management in obesity, there are no approved products combining all three agents into a single formulation; however, they may be used together off-label in clinical practice for patients with obesity and comorbidities such as type 2 diabetes[3][6][9]. The combination targets both appetite suppression (phentermine/topiramate) and glycemic control (metformin).